Yasuaki Anami

11PUBLICATIONS
31CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Characterisation of biological macromoleculesHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 07, 2025
177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors.

Aiko Yamaguchi, Chisato M Yamazaki, Yasuaki Anami

|Dec 18, 2024
Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer.

Joan Jacob, Yasuaki Anami, Peyton C High

|Jan 09, 2024
Exploring the next generation of antibody-drug conjugates.

Kyoji Tsuchikama, Yasuaki Anami, Summer Y Y Ha

|Jul 06, 2022
An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.

Summer Y Y Ha, Yasuaki Anami, Chisato M Yamazaki

|Apr 15, 2022
Homogeneous antibody-angiopep 2 conjugates for effective brain targeting.

Yasuaki Anami, Wei Xiong, Aiko Yamaguchi

|Jun 11, 2021
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance.

Chisato M Yamazaki, Aiko Yamaguchi, Yasuaki Anami

Pageof 2

Frequent Collaborators

10 joint publications

Kyoji Tsuchikama

6 joint publications

Chisato M Yamazaki

6 joint publications

Ningyan Zhang

4 joint publications

Zhiqiang An